黑色素瘤前哨淋巴结活检后无复发生存与黑色素瘤特异性生存预测模型的外部验证
该研究在国际多中心独立队列中验证了一个预测黑色素瘤患者前哨淋巴结活检后5年无复发生存(RFS)和黑色素瘤特异性生存(MSS)的模型。外部验证队列纳入6174例患者,模型对RFS和MSS的ROC曲线下面积分别为0.76和0.79,校准良好,决策曲线分析显示在45%复发概率阈值下具有净获益。
要点
- 模型在6174例国际多中心队列中验证,RFS的AUC为0.76,MSS的AUC为0.79。
- 校准斜率RFS为0.98、MSS为0.99,预测与实际5年生存率高度一致。
- 在45%复发概率阈值下,模型较「全部治疗」策略提供净获益。
核心结论
- 该模型在大型异质性独立队列中表现出良好预测性能,稳健性得到证实。
- 决策曲线分析显示模型较「全部治疗」策略有明确净获益,具有临床使用潜力。
研究设计与样本
- 外部验证研究,分析前哨淋巴结工作组(SLNWG)数据库中的黑色素瘤患者。
- 排除临床III期、有其他恶性肿瘤史或随访期间接受伴随系统性治疗的患者。
- 外部验证队列共6174例患者,来自美国、欧洲和以色列。
主要发现
- 前哨淋巴结阳性患者788例(12.8%)。
- RFS的ROC曲线下面积为0.76(95%CI 0.74-0.77),MSS为0.79(95%CI 0.76-0.81)。
- 校准良好,RFS校准斜率0.98,MSS校准斜率0.99,观察5年生存率与预测值接近。
- 在预设45%复发概率阈值下,模型较「全部治疗」和「不治疗」策略提供净获益。
临床怎么用
- 该模型可用于黑色素瘤前哨淋巴结活检后患者的5年RFS和MSS预测,辅助临床决策。
- 在45%复发概率阈值下,模型可帮助识别可能从治疗中获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, a model to predict 5-year recurrence-free survival (RFS) and melanoma-specific survival (MSS) after sentinel lymph node biopsy (SLNB) was published. The aim of this study was to validate that model in a large independent international cohort. METHODS: The database of the Sentinel Lymph Node Working Group (SLNWG) was analysed for patients with malignant melanoma who underwent SLNB. Patients with clinical stage III melanoma, a history of other malignancies, or receiving concomitant systemic therapies during follow-up were excluded. The model's predictive performance was evaluated using discrimination and calibration metrics in the eligible cohort. Decision curve analysis was performed to assess the clinical value of the model. RESULTS: The external validation cohort consisted of 6174 patients of the SLNWG from the USA, Europe, and Israel. A positive sentinel node was found in 788 patients (12.8%). The area under the time-dependent receiver operating characteristic (ROC) curve of the external validation was 0.76 (95% c.i. 0.74 to 0.77) for RFS and 0.79 (95% c.i. 0.76 to 0.81) for MSS. The model was well calibrated, as the observed 5-year survival rates aligned closely with the predicted survival rates (calibration slope of 0.98 for RFS and calibration slope of 0.99 for MSS). The model provided a net benefit versus the 'treat all' and 'treat none' strategies at the predetermined probability threshold for recurrence of 45%. CONCLUSION: The model demonstrated good performance in a large heterogeneous independent cohort, emphasizing its robustness. Decision curve analysis revealed a clear net benefit of the model over a treat all strategy, highlighting its potential for clinical use.
引用
- Stassen RC, Maas CCHM, Leong SP, et al. External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy. Br J Surg. 2025. PMID: 40243383. doi:10.1093/bjs/znaf037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。